Therapeutic approaches for prion and Alzheimer's diseases.
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesPreventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Immunomodulation for prion and prion-related diseases.High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brainsAntibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.AD vaccines: conclusions and future directions.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.Immunotherapy for prion diseases: opportunities and obstacles.The development of new therapeutics for Alzheimer's disease.Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases.Overexpression of p62/SQSTM1 promotes the degradations of abnormally accumulated PrP mutants in cytoplasm and relieves the associated cytotoxicities via autophagy-lysosome-dependent way.Strain conformation controls the specificity of cross-species prion transmission in the yeast modelHuman anti-prion antibodies block prion peptide fibril formation and neurotoxicity.Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.Quantitative reverse-transcription polymerase chain reaction analysis of Alzheimer's-associated genes in mouse scrapie.
P2860
Q24289511-90F47DCF-99BF-4C6F-AFFC-403233564A3DQ30855109-49E9E28B-7CED-4607-ADD4-4B0675E86FA1Q34171325-630546A9-C88C-4E1E-81E8-1DBA171C2559Q34286572-6DC74C03-BB49-4E4B-982B-F24CAF43B95CQ34565644-11D6521A-0C9E-4523-A880-484F45E7C23CQ36776046-EC2FF3F4-719D-4B44-AB57-B88786EE1D8BQ36802573-90391202-B3B2-4A77-AAB8-9FDE33D2F145Q37267918-870CA6D8-A0DC-496E-812A-E46D58555979Q37438273-BDE59458-7F09-4118-8BCF-2522F1B1383EQ37655247-BB73DD1D-5511-41E3-B95E-5E6A404D530CQ37681432-233EC179-AA10-47DF-ACAC-FDA56CD238E3Q37752915-E1CE43C1-842B-433D-84E0-583D4B6E82A7Q37773260-988E756C-2788-4525-BD9E-DAF7511A4FACQ37784685-DB8BB83E-EEAE-456C-91A5-096F748975AFQ38234645-C525AD61-B9FD-4409-B3BC-0B9911CD22D0Q39062404-4A288272-7BE6-42F3-9FF7-B7483D83E4C4Q40561872-5BA678AB-B767-4412-89FC-80F701963545Q41975386-C4620C49-BA43-4B8C-9346-31D0561E4959Q43074512-1BB63EE1-FCA6-4E0C-89AB-EF6BAA08BAD5Q43288312-9F82AD5D-3BAD-4DB7-9B36-FAEA568A509A
P2860
Therapeutic approaches for prion and Alzheimer's diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Therapeutic approaches for prion and Alzheimer's diseases.
@en
type
label
Therapeutic approaches for prion and Alzheimer's diseases.
@en
prefLabel
Therapeutic approaches for prion and Alzheimer's diseases.
@en
P2860
P1433
P1476
Therapeutic approaches for prion and Alzheimer's diseases.
@en
P2093
Einar M Sigurdsson
Thomas Wisniewski
P2860
P304
P356
10.1111/J.1742-4658.2007.05919.X
P407
P577
2007-07-06T00:00:00Z